Novo Nordisk Shares Surge 5% After Positive Ozempic Study

The study shows that the medication Ozempic reduces the risk of heart attack, stroke and death more than a competitor from the American Eli Lilly.

Ozempic reduces these risks by 23 percent compared to competitor Lilly's dulaglutide, according to Novo Nordisk with reference to the first direct comparative study in real life.